PDCD1 and melanoma: These data provided the rationale for exploring fianlimab in combination with cemiplimab in this phase 1 trial, further supported by recent results showing improved median progression-free survival and objective response rate (ORR) with combined nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) compared with anti-PD-1 monotherapy in patients with treatment-naïve advanced melanoma (11).